Johnson & Johnson (NYSE:JNJ) was downgraded by stock analysts at Vetr from a “hold” rating to a “sell” rating in a research report issued on Monday. They currently have a $130.49 price objective on the stock. Vetr‘s price objective indicates a potential downside of 3.50% from the stock’s previous close.
A number of other equities analysts have also weighed in on the company. UBS AG reaffirmed a “buy” rating and issued a $148.00 price objective (up previously from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. BMO Capital Markets reaffirmed a “buy” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 1st. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Johnson & Johnson in a research note on Sunday, May 21st. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $134.50.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 135.22 on Monday. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The firm has a 50 day moving average price of $132.79 and a 200 day moving average price of $129.43. The stock has a market cap of $362.93 billion, a PE ratio of 22.88 and a beta of 0.79.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.74 earnings per share. On average, equities analysts expect that Johnson & Johnson will post $7.18 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Rating Lowered to Sell at Vetr Inc.” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/20/johnson-johnson-jnj-rating-lowered-to-sell-at-vetr-inc.html.
In other news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp grew its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. BlackRock Inc. grew its stake in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. Janus Henderson Group PLC grew its stake in Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after purchasing an additional 3,289,763 shares in the last quarter. Vanguard Group Inc. grew its stake in Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after purchasing an additional 2,581,562 shares in the last quarter. Hedge funds and other institutional investors own 65.90% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.